BioSpace News Archive

Drug Development

COVID Update: U.S. Exceeds 400 Million Vaccine Doses and Waning Efficacy

Between the numerous COVID-19 vaccines and several new antiviral drugs, it would appear that the tools to end the COVID-19 pandemic are within reach. Here’s a look at some of the top stories.

November 15, 2021
·
6 min read
·
Mark Terry
BioCapital

Discovery of 17 Genes Implicated in Obesity Could Lead to Breakthrough Treatments

Scientists from the University of Virginia recently revealed the discovery of 17 total genes directly implicated in the development of obesity.

November 15, 2021
·
5 min read
·
Kaylei Whalen
Drug Development

ACELYRIN Scores $250 Million to Progress Innovative Antibody Mimetic

Los Angeles-based ACELYRIN, Inc. announced a quarter-million dollars in Series B financing Tuesday morning, along with a splashy licensing deal.

November 15, 2021
·
3 min read
·
Heather McKenzie
BioMidwest

BioSpace’s Inaugural Best Places to Work Report Reveals Industry’s Top Choice Employers

This year’s top 30 large and small companies operate in some of the Life Sciences’ hottest spaces – precision medicine, vaccines, gene editing, genomics and oncology.

November 15, 2021
·
3 min read
·
Heather McKenzie
Business

Recludix Launches to Solve Elusive Targets; Twist Spins Out Revelar

Recludix launches with a mission to develop Three SH2 domain inhibitor programs targeting STAT3, STAT6, and an undisclosed non-STAT target for cancer and inflammatory disease targets.

November 15, 2021
·
2 min read
·
Alex Keown
FDA

FDA Approves New PV Therapy BESREMi After Protracted Tug-of-War

The research showed that 61% of patients with PV experienced a complete hematological response after 7.5 years of treatment with BESREMi. Here’s more about it.

November 15, 2021
·
4 min read
·
Vanessa Doctor, RN and Alex Keown
Merck’s Anti-Cholesterol Drug Threatens Esperion, Other PCSK9 Inhibitor Makers

PCSK9 inhibitors have had trouble gaining tracking in the marketplace. Since about 2015, a number of companies have received approval for these drugs but struggled with sales.

November 15, 2021
·
3 min read
·
Mark Terry
Business

Flagship’s Noubar Afeyan Aims to Answer Science’s ‘What if’ Questions

Flagship Pioneering Founder and CEO Noubar Afeyan has been behind the launch of dozens of companies, some of which, such as Moderna, have become a household name across the globe.

November 15, 2021
·
2 min read
·
Alex Keown
Policy

Seniors Bear Burden of Biogen’s Alzheimer’s Drug in Medicare Price Hike

Thanks partly to Biogen’s pricey new Alzheimer’s drug, Medicare enrollees will be burdened with higher monthly premiums for their Part B coverage.

November 15, 2021
·
3 min read
·
Kate Goodwin
Business

Kiora Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (“Kiora” or the “Company”) today reported its financial results for the quarter ended September 30, 2021 and provided an update on recent corporate and operational activities.

November 15, 2021
·
6 min read